OMEICOS Therapeutics

High-Level Overview

OMEICOS Therapeutics is a Berlin-based clinical-stage biopharmaceutical company developing first-in-class small-molecule therapeutics that target natural cell-protective pathways derived from omega-3 fatty acid metabolism, specifically stabilized synthetic analogues of epoxyeicosanoids.[1][2][5] Its lead asset, OMT-28, is an orally available compound with strong anti-inflammatory activity, improved mitochondrial function, and anti-fibrotic effects, addressing cardiovascular, inflammatory, mitochondrial, ophthalmic, and renal diseases with high unmet needs.[3][4][5] OMEICOS serves patients with conditions like persistent atrial fibrillation, primary mitochondrial diseases (PMD), coronary artery disease, and myopathy/cardiomyopathy, solving problems of organ protection, inflammation reduction, and mitochondrial dysfunction through a novel mechanism that outperforms natural epoxyeicosanoids in bioavailability and activity.[1][2][5] The company demonstrates strong growth momentum, with rapid clinical progress—including Phase II trials initiated since 2019, recent completion of enrollment in the PMD-OPTION Phase II study (top-line data expected mid-2025), and secured financings like a EUR 17 million Series C in 2018—achieved via a lean organization in under six years from spin-out to proof-of-concept.[1][3]

Origin Story

OMEICOS was spun out in June 2013 from the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, Germany, to commercialize breakthroughs in omega-3 fatty acid-derived epoxyeicosanoids for therapeutic use.[1][2] The founding scientific team includes experts Dr. Wolf-Hagen Schunck, Prof. John R. Falck, Prof. Dominik Müller, and Dr. Robert Fischer, whose research at MDC and UT Southwestern established the foundational IP on these bioactive lipid mediators' role in organ protection.[2][3] OMT-28 was selected as the lead compound in July 2014 after preclinical assessment, with a US subsidiary formed in October 2017 to support North American operations.[1] Early traction came swiftly: Phase I first-in-human data in July 2018 showed compelling safety, enabling Phase II in atrial fibrillation by April 2019, bolstered by Series B and C financings from investors like Forbion and REMIGES Ventures.[1][2]

Core Differentiators

• Novel Mechanism and Multi-Target Profile: OMT-28 activates cell type-specific endogenous pathways for tissue protection, with superior metabolic stability, oral bioavailability, and pharmacokinetic properties over natural epoxyeicosanoids; it reduces inflammation (e.g., GDF-15, IL-6 biomarkers), improves mitochondrial function, and combats fibrosis across cardio-, renal-, metabolic-, and ophthalmic models.[2][4][5]
• Rapid, Efficient Development: Lean organization advanced from spin-out (2013) to Phase II proof-of-concept in under six years, with excellent safety in Phase I (75 healthy volunteers) and Phase II atrial fibrillation trials.[1][5]
• Robust IP and Pipeline: Exclusive worldwide licenses from MDC and UT Southwestern for OMT-28 and preclinical compounds; supported by BMBF grants and VC consortium.[3]
• Broad Applicability: Phase II data in PMD (enrollment complete, mid-2025 readout) and atrial fibrillation validate safety/tolerability; expansions planned for coronary artery disease and ophthalmology.[1][3][5]
• Experienced Leadership: Complementary team covers clinical, scientific, operational, and business expertise.[1]

Role in the Broader Tech Landscape

OMEICOS rides the wave of precision medicine targeting lipid mediators and mitochondrial health, capitalizing on growing recognition of omega-3 derivatives' role in resolving chronic inflammation—a key driver of cardiovascular and metabolic diseases amid rising global burdens like atrial fibrillation and PMD.[2][5] Timing aligns with advances in biomarker-driven trials (e.g., IL-6/GDF-15 reductions linked to CV mortality) and demand for orally available, multi-indication therapies post-COVID inflammation insights.[1][5] Favorable market forces include biotech VC resurgence in Europe, regulatory nods (e.g., Phase II allowances in 2022-2023), and synergies with aging populations driving cardio-mitochondrial needs.[1][3] By validating epoxyeicosanoids clinically, OMEICOS influences the ecosystem, potentially unlocking broader omega-3 platforms and inspiring spin-outs from academic centers like MDC.[2]

Quick Take & Future Outlook

OMT-28's mid-2025 PMD top-line data could catalyze partnerships or further financings, paving Phase IIb/III in cardiology and ophthalmology proof-of-concepts.[3][5] Trends like AI-accelerated drug discovery and inflammation-CV outcome linkages will amplify its multi-target edge, with influence evolving toward Big Pharma licensing or acquisition as safety data de-risks the pipeline. This positions OMEICOS to deliver on its promise of transformative cell protection, bridging academic innovation to clinical impact in unmet cardio-inflammatory spaces.[1][5]